While some might accuse the field of being over-hyped, immuno-oncology continues to attract attention and investment for its potential to cure cancer. What new therapies are European biotech cooking up?

Since the dawn of immuno-oncology broke with checkpoint inhibitors, innovative therapies like Keytruda and Rituxan from big pharma have taken the world by storm. European biotech’s pipeline is full of potential successors born from T-Cell Receptors (TCR), monoclonal antibodies (mAbs), T-Cell Fragments, Chimeric Antigen Receptor-modified T cells (CAR-T) and tumor-infiltrating lymphocytes (TIL).

Medigene is leading the TCR race, with Immunocore not far behind with its fragments. Celyad and Cellectis are fierce rivals in CAR-T therapy and in a dead heat. The antibody pipeline is jam-packed with biotechs at every stage of development. TILs are a lesser-known area of immuno-oncology, but Cellular Therapeutics has developed one of the most advanced programs in the field.

Check out how far companies and their therapies have come in immuno-oncology!

Major thanks to our guides and Accellerate Partners for their input! Please note that this infographic is not meant to be comprehensive.

Note: TILT is sponsoring a trial in which the TIL is bolstered with an oncolytic virus.

Infographic by Justine Braguy ; Image from Agor2012/shutterstock.com

Previous post

This Musician Plays Piano Duets with a Microorganism

Next post

To the Rescue: A Final Phase III Success for Post-Operative Nausea

  • Hans

    Great start guys, but seems a very short list. Novartis, Gadeta, TxCell, GSK (Okairos) should at least be added. Also as a category “cancer vaccines.”

  • Dieter Hovekamp

    It is a start – but needs some rearrangements: Adaptimmune is the clear leader in TCR T-cell therapy ( ~10 clinical TCR trials) worldwide and close up is only Immunocore.
    Medigene in this area has many nice preclinical assets and ideas only – a first phase I expected this year – the advanced projects AAVLP and most of its oncolytic Virus developments have been sold to other investors and Amgen.

  • Pierre

    Thanks for this great summary! At some point, it would be good to have a comparative table/infographic with the US for example

  • Alex

    L’approche de Celyad est unique. Utiliser les ligands de l’immunité innée sur des cellules T. Ce qui revient à associer les particularités des deux systèmes de défense du corps .

  • Dieter Hovekamp

    BTW – in case of an update – make sure you get multi-specifics in your chart. Most prominent in Europe beside Micromeds Blinatumomab (bought by Amgen and sold as Blincyto®) are Affimed with its T-cell and NK-cell engagers, Pieris with it’s Anticalins combining checkpoint-inhibitors and other modifiers in the TME (Tumor Micro Environment). Also of interest other recent TME players like Noxxon Pharma with its Spiegelmers.
    For a good review on BsAbs in cancer immunotherapies http://www.mdpi.com/2073-4468/5/1/1/htm

  • Andy Reed

    Your missing Scancells 2 platforms here
    ImmunoBody and Moditope

    • Thanks Andy! However, this infographic is not meant to be comprehensive.